UPDATE: Morgan Stanley Reiterates On Idenix Pharmaceuticals Due To Likely Merck Acquisition

Loading...
Loading...
In a report published Tuesday, Morgan Stanley analyst David Friedman reiterated an Equal-Weight rating on
Idenix PharmaceuticalsIDIX
, and raised the price target from $5.00 to $24.50. In the report, Morgan Stanley noted, “We are increasing our price target to $24.50 in light of Merck's announced bid for Idenix at $24.50/share. We do not expect other bidders for this company or any data to cause the deal to not happen...We are Equal-weight IDIX and have a $24.50 price target, which is driven by Merck's announced acquisition price for Idenix. We do not expect other bidders for Idenix.” Idenix Pharmaceuticals closed on Monday at $23.80.
Posted In: Analyst ColorPrice TargetAnalyst RatingsDavid FriedmanMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...